Summary of ASH 2019

Jack Aiello |

Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early Tuesday morning describing a phase III trial called Candor for relapsed/refractory multiple myeloma patients (RRMM), comparing (Kyprolis) carfilzomib and dexamethasone with or without Darzalex (daratumumab). The abstract #LBA-6 showed that the addition of dara decreased the risk […]